{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037794","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-08-13T20:20:20+00:00","discovered_at":"2026-08-13T20:21:00.358813+00:00","generated_at":"2026-08-13T20:21:11.226321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ensysce Q2 net loss $2.6M; completes Cy Biopharma acquisition adding CY200, $77M funding","bullets":["Completed acquisition of Cy Biopharma on Aug 6, 2026, adding CY200 (Orphan Drug-designated for CRPS) as lead asset; up to $77M in new funding.","Q2 2026 net loss $2.6M vs $1.7M; cash $0.7M at June 30, 2026 vs $4.3M at Dec 31, 2025.","Post-quarter-end acquisition and financings provided ~$31M net cash; runway into late 2027, second tranche up to $38.6M on milestones.","R&D expenses $2.5M (up from $1.9M); federal grants $1.2M; NIDA grant third year awarded, total $26M over six years.","Taiwan patent for MPAR through 2042; PF614-301 Phase 3 trial ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037794","json":"https://secwatch.observer/filing/0001493152-26-037794.json","markdown":"https://secwatch.observer/filing/0001493152-26-037794.md","text":"https://secwatch.observer/filing/0001493152-26-037794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/0001493152-26-037794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:21:11.226321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}